Author: Ballell, Lluis ; Remuiñán, Modesto J. ; Rullas, Joaquín ; Deprez, Benoit ; Tanina, Abdalkarim ; Frita, Rosangela ; de Mercado, Jaime ; Soetaert, Karine ; Jiménez, Elena ; Willand, Nicolas ; Djaout, Kamel ; Baulard, Alain R. ; Drewes, Gerard ; Casado, Patricia ; Flipo, Marion ; Gamallo, Pablo ; Porras-De Francisco, Esther ; Kiass, Mehdi ; Brodin, Priscille ; Megalizzi, Véronique ; Boesche, Markus ; Leroux, Florence ; Slupek, Stéphanie ; Gresham, Stephanie ; Antoine, Rudy ; Boyle, Gary W. ; Mendoza-Losana, Alfonso ; Moune, Martin ; Mathys, Vanessa ; Wintjens, René ; Delorme, Vincent ; Bourotte, Marilyne ; Ghidelli-Disse, Sonja ; Barros-Aguirre, David ; Kemmer, Christian ; Lociuro, Sergio ; Piveteau, Catherine ; Gitzinger, Marc ; Pérez-Herrán, Esther ; Derimanov, Geo ; Martínez-Martínez, María S.

The sensitivity of Mycobacterium tuberculosis , the pathogen that causes tuberculosis (TB), to antibiotic prodrugs is dependent on the efficacy of the activation process that transforms the prodrugs into their active antibacterial moieties. Various oxidases of M. tuberculosis have the potential to activate the prodrug ethionamide. Here, we used medicinal chemistry coupled with a phenotypic assay to select the N-acylated 4-phenylpiperidine compound series. The lead compound, SMARt751, interacted with the transcriptional regulator VirS of M. tuberculosis , which regulates the mymA operon encoding a monooxygenase that activates ethionamide. SMARt751 boosted the efficacy of ethionamide in vitro and in mouse models of acute and chronic TB. SMARt751 also restored full efficacy of ethionamide in mice infected with M. tuberculosis strains carrying mutations in the ethA gene, which cause ethionamide resistance in the clinic. SMARt751 was shown to be safe in tests conducted in vitro and in vivo. A model extrapolating animal pharmacokinetic and pharmacodynamic parameters to humans predicted that as little as 25 mg of SMARt751 daily would allow a fourfold reduction in the dose of ethionamide administered while retaining the same efficacy and reducing side effects.

100 Deals associated with SMARt-751

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tuberculosis	Preclinical	DE	Cellzome AG	03 May 2022
Tuberculosis	Preclinical	CN	GlaxoSmithKline (China) R&D Co., Ltd.	03 May 2022
Tuberculosis	Preclinical	CH	BioVersys AG	03 May 2022
Tuberculosis	Preclinical	FR	Institut Pasteur de Lille	03 May 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SMARt-751

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation